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Abstract 
Expression of the cellular prion protein (PrPC) is crucial for the development of prion 
diseases. Resistance to prion diseases can result from reduced availability of the prion protein 
or from amino acid changes in the prion protein sequence. We propose here that increased 
production of a natural PrP α-cleavage fragment, C1, is also associated with resistance to 
disease. We show, in brain tissue, that ARR homozygous sheep, associated with resistance to 
disease, produced PrPC comprised of 25% more C1 fragment than PrPC from the disease-
susceptible ARQ homozygous and highly susceptible VRQ homozygous animals. Only the 
C1 fragment derived from the ARR allele inhibits in-vitro fibrillisation of other allelic PrPC 
variants. We propose that the increased α-cleavage of ovine ARR PrPC contributes to a 
dominant negative effect of this polymorphism on disease susceptibility. Furthermore, the 
significant reduction in PrPC β-cleavage product C2 in sheep of the ARR/ARR genotype 
compared to ARQ/ARQ and VRQ/VRQ genotypes, may add to the complexity of genetic 
determinants of prion disease susceptibility. 
 
Abbreviations 
PrPC , cellular prion protein; CNS, central nervous system; CJD, Creutzfeldt-Jakob disease; 
CWD, chronic wasting disease; BSE, bovine spongiform encephalopathy; PrPSc, disease 
associated misfolded prion protein; NPU, Neuropathogenesis Unit; AHVLA, Animal Health 
and Veterinary Laboratories Agency; PMSF, phenylmethanesulfonylfluoride; NEM, N- 
ethylmaleimide; PNGase F, Peptide:N-glycosidase F; TBS, Tris-buffered saline; TBST, TBS-
Tween; ALP, Alkaline Phosphatase; IPTG, isopropylthio-β-galactoside; HPLC, High pressure 
liquid chromatography; MES, 2-(N-Morpholino)ethanesulfonic acid sodium salt; ThT, 
Thioflavin T. 
 
Keywords:  
prion; transmissible spongiform encephalopathy; fibrillisation; protein-cleavage 
 
1. Introduction 
The prion protein, PrPC, is encoded by the PRNP gene and is expressed at high levels in the 
central nervous system (CNS) and to a lesser degree in peripheral tissues in all mammalian 
species. The biological function of PrPC is not clear, but roles in promoting cell survival, 
signal transduction and alleviating oxidative stress have been suggested [1-3]. PrPC is 
essential for the pathogenesis of a group of disorders called prion diseases, also known as 
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transmissible spongiform encephalopathies (TSEs). TSEs are fatal, neurodegenerative 
protein-misfolding diseases caused by unconventional infectious agents, often referred to as 
prions [4,5]. Naturally occurring prion diseases are Creutzfeldt-Jakob disease (CJD) in man, 
chronic wasting disease (CWD) in deer, bovine spongiform encephalopathy (BSE) in cattle 
and scrapie in sheep. A marker of prion disease infection is the slow accumulation of a 
protease-resistant isoform of the prion protein, designated PrPSc, in the CNS and the 
peripheral lymphoid system [6]. PrPSc is converted from PrPC by a seeded polymerisation 
mechanism leading to a range of morphologically different aggregates, ranging from fibrils to 
diffuse amyloid plaques [7]. The process can be mimicked in vitro, whereby recombinant 
PrPC can be induced to transit from a soluble alpha-helical state into insoluble, highly ordered 
amyloid fibrils by a nucleation-dependent mechanism [8]. Most mammalian species exhibit 
PRNP gene polymorphisms which encode PrPC protein sequence variants and several of these 
have been shown to modulate susceptibility, incubation period or pathology of prion diseases 
[9]. One of the best described genetic associations between PRNP gene polymorphisms (PrPC 
variants) and prion diseases applies to sheep scrapie. Although the genetic determinants of 
susceptibility to scrapie infection and incubation period length in sheep are highly complex, 
involving more than ten polymorphic positions, three substitutions of major importance are in 
codons 136, 154 and 171. Ovine PrPC variants are therefore described by the amino acid 
expressed at these codons, such as A136R154R171 (ARR), ARQ and VRQ etc. [10-12]. It is still 
a matter of debate exactly how PrPC amino acid substitutions cause differences in disease 
susceptibility and pathogenesis. The efficiency of in-vitro conversion of PrPC to PrPSc has 
been shown to vary for different PrPC variants [13-15] and it has been suggested that this 
variation is linked to differential protein stability [14], but it is likely that in vivo additional 
factors contribute to disease phenotype differences. 
Ovine PrPC is expressed in brain as di- (33-35 kDa), mono- (30-32 kDa) or un-glycosylated 
(27 kDa) protein in variable ratios. Cellular processing of PrPC involves two well-documented 
proteolytic cleavage events. For ovine PrPC, α-cleavage of the peptide-bond between His114 
and Val115 [18,19] creates two polypeptides, of which C1 is the C-terminal fragment that 
resides alongside full length PrPC on the cell membrane [20]. C1 also appears in di- (25-
27kDa) mono- (21-23kDa) and un-glycosylated (17kDa) forms [21-23]. The majority of the 
corresponding N-terminal, 9kDa N1 fragment is released from the cell by shedding [24]. The 
products of α-cleavage of PrPC have been observed in the brains of a variety of mammals 
with diverse susceptibility to TSE diseases [20-22, 25-27]. An alternative β-cleavage, at Gly92 
of ovine PrPC, generates the fragments C2 and N2, but occurs at a much lower level in 
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healthy animals than α-cleavage and appears to be a response to oxidative stress [28]. It is a 
long held view that prion disease incubation periods are correlated with the amount of PrPC. 
This has been demonstrated in various transgenic mouse models in which incubation periods 
of experimentally induced prion diseases are inversely correlated with the PrPC protein 
expression [29, 30]. However, often in these studies the levels of full-length PrPC and its 
proteolytic fragments have not been differentiated. Recently it was shown conclusively that 
the C1 fragment itself does not convert into a protease-resistant isoform in scrapie challenged 
transgenic mice expressing only C1. Furthermore, when the C1 fragment was co-expressed 
with full-length PrPC incubation periods were extended [31]. It has also been shown that cell 
lines with naturally higher levels of α-cleavage show enhanced resistance to prion infection 
[32]. This raises the possibility that PrPC cleavage may control disease by either reducing the 
amount of full length PrPC available for conversion or by producing different levels of the C1 
fragment, which would act as inhibitory modulators of conversion. In sheep, this control is 
likely to be associated with PRNP genotype. We have found that proteolytic processing of 
ovine PrPC is PRNP genotype dependent, with increased amounts of the C1 fragment and 
decreased amounts of the C2 fragment in brain tissue from sheep associated with resistance to 
scrapie. Furthermore, we have shown that a recombinant protein comprising the C1 fragment 
derived from the ovine ARR variant has the ability to inhibit or delay fibrillisation of full 
length PrP, a key step in the formation of disease associated amyloid. 
 
2. Material and methods 
2.1 Brain tissue preparations 
Sheep used in this study were obtained from the Roslin Institute Cheviot flock (formerly 
known as the NPU Cheviot flock) [33] and from a scrapie free flock (AHVLA)  (both 
together in this paper called Roslin sheep) or from random sampling at Norwegian abattoirs 
(in this paper called Norwegian sheep). All sheep were arginine homozygous in codon 154 
(RR154). The VRQ/VRQ, VRQ/ARQ and ARQ/ARQ genotypes are collectively referred to as 
QQ171, the ARR/ARR genotype as RR171. For some Roslin sheep we retained 1 cm mid-
sectional slices from the left side of the brain, from which cores of approximately 5 mm 
diameter were removed from the cortex, cerebellum, medulla, thalamus, hypothalamus, mid 
brain and pons. Following post mortem, all tissues were immediately stored at -70 °C. 
Tissues were manually homogenised in lysis buffer (5 % NP-40 (v/v), 12.1 mM Sodium 
deoxycholate in PBS) with protease inhibitors (10 µM PMSF, 10 µM NEM or Complete Mini 
Tablets, Roche) to make a 10 % (w/v) homogenate. The homogenate was clarified by 
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centrifugation at 2000 rpm at 4 ºC for 10 minutes, the supernatant was collected, flash frozen 
and stored at -20 °C until further analysis. 
2.2 Antibodies 
Anti-PrP monoclonal antibodies BC6, JB10 and FH10 against PrP epitopes 136-154, 216-225 
and 198-207, respectively were kindly gifted by Dr Sandra McCutcheon, The Roslin 
Institute. For immunoblotting, antibodies were used at the following final concentrations in 
0.5% (v/v) blocking reagent (Western Blocking Reagent 10 %, Roche in Tris buffered saline, 
pH 7.5); BC6 0.1 µg/ml, JB10 0.9 µg/ml, FH10 0.5 µg/ml, P4 (Biopharm) 0.2 µg/ml,  6H4 
(Biopharm) 0.1 µg/ml, Anti- Murine α-tubulin IgG1 (Fisher Scientific) 0.01 µg/ml, 
horseradish-peroxidase-conjugated rabbit anti-mouse (Stratech, UK) 0.08 µg/ml. Bar224 
(Bertin Pharma, SpiBio, France) which binds to the globular domain of PrP was used at a 
concentration of 1 µg/ml, diluted in TBS with 1% fat-free dry milk, overnight at 4°C.  
2.3 Deglycosylation  
Brain homogenate (10 % w/v) was denatured at 100 ºC for 10 minutes and incubated with 
0.125 U of peptide N-glycoside F (PNGase F kit, New England Biolabs) for 2 hours at 37 ºC 
according to manufacturer’s instructions. Deglycosylated protein was isolated using methanol 
precipitation and stored at -20 ºC. Before immunoblotting, the protein was pelleted by 
centrifugation at 10,400 g for 10 minutes. Prior to electrophoresis, samples were boiled 
directly in NuPAGE (Invitrogen) sample buffer supplemented with a reducing agent 
(Invitrogen).  
2.4 SDS PAGE –Immunoblotting 
Deglycosylated protein was denatured at 70 ºC for 10 minutes and separated by 12% 
NuPAGE Bis-Tris gels (Invitrogen) or 12% Criterion gels (BioRad). Molecular markers 
spanning 20-220 kDa were used for size reference (MagicMarker XP Western protein 
Standard, Invitrogen) and electrophoresis was performed in an Xcell SureLock tank at 150 V 
for 1 hour using a NuPAGE kit (Invitrogen) or with the BioRad Criterion system (BioRad). 
Proteins were transferred onto poly(vinylidenedifluoride) membranes (Millipore or GE 
Healthcare) at 25 V for 1 hour, after which the membranes were washed with TBS (50 mM 
Tris, 150 mM NaCl, pH 7.5). The membranes were blocked using 1 % (v/v) blocking solution 
for 1 hour at room temperature with agitation followed by incubation with anti-PrP antibodies 
diluted in 0.5 % (v/v) blocking solution under the same conditions.  Membranes were washed 
with TBST (0.1 % Tween 20 in TBS) followed by 0.5 % (v/v) blocking solution. The 
membranes were incubated in horseradish-peroxidase-conjugated rabbit anti-mouse (Stratech, 
UK) or ALP conjugated goat-anti-mouse IgG (BioRad) diluted at 1:10000 in 0.5 % (v/v) 
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block for 75 minutes. The membranes were washed in TBST and proteins were visualized 
using activated chemiluminescence (SuperSignal West Dura Extended Duration Substrate, 
Thermo Scientific) Lumi-Film Chemiluminescent Detection Film (Roche) or fluorescence 
(ALP substrate, ECF, GE Healthcare), recorded with a variable mode imager (Typhoon, GE 
Healthcare), when secondary antibodies labeled with ALP were used. For quantitative 
analysis, blots were scanned and the net intensity of manually selected protein bands 
representative of full length PrPC, C1 and C2 were measured by use of Kodak MI software. In 
the case of fluorescence scans, the Image Quant Utility software (GE Healthcare) was used. 
The combined signal of all bands for each sample was taken as 100% and each band 
calculated as a percentage of the total signal. For each animal deglycosylation, 
immunoblotting and densitometry were performed at least twice and any further analysis was 
based on the average C1 value. 
2.5 Production of C1 recombinant proteins  
We have previously published details of full-length ovine PrP constructs [34]. Briefly, PrP 
open reading frame from codons 25-233 was inserted into a pTrcHis B vector and expressed 
in Escherichia coli strain Rosetta (DE3). To produce truncated recombinant PrP proteins 
representative of the C1 fragment the open reading frame between codons 115 and 234 of 
ovine PRNP from three genotypes (ARR/ARR, VRQ/VRQ and ARQ/ARQ) was amplified 
by PCR from genomic DNA with oligonucleotide primers Nde_C1F 
(CATCATATGGTGGCAGGAGCTGCTG) and BamH1_C1R 
(AGTGGATCCTCAACTTGCCCCCCTTTG) and high fidelity Taq polymerase. The 
fragments were cloned into the PET 19b vector (Invitrogen) and transformed into Escherichia 
coli strain BL21 (DE3). The sequences of all plasmid constructs were confirmed by 
sequencing with T7 oligonucleotide (TAATACGACTCACTATAGG) on an AB3130 Genetic 
Analyzer with the BigDye® terminator v3.1 cycle sequencing kit (Applied Biosystems, 
USA). E.coli were cultured in terrific broth (TB) to an optical density of between 0.6-0.8 and 
PrP expression was induced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to 
a final concentration of 1 mM. Bacterial lysis was performed using lysozyme and inclusion 
bodies containing recombinant proteins were isolated and stored at -20 ˚C - the full details of 
which are described in Kirby et al (2006) [34]. Inclusion bodies were solubilised in a urea 
based buffer (urea 8 M, disodium hydro-phosphate 0.1 M, Tris-base 10 µM, pH8 with 2-
mercaptoethanol). The full method for purification of these recombinant proteins has been 
previously published [35]. Briefly, recombinant proteins were first purified by nickel ion 
affinity chromatography, followed by desalting using a HiPrep desalting column. Proteins 
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were oxidised overnight and further purified by reverse phase HPLC chromatography. 
Purified protein was lyophilised and stored at -20 ˚C. All protein variants were expressed and 
purified on two separate occasions to ensure reproducibility of results. 
2.6 Circular Dichroism 
Measurements of purified protein (~0.5 mg/ml) in 50 mM sodium acetate were made using a 
Jasco J-710 spectropolarimeter with a path length of 0.2 mm. Readings were collected from 
260 nm to 200 nm, with 20 scans repeated for each reading at a rate of 100 nm/min. 
Observations were made about protein secondary structure by comparison of the spectral 
output with proteins of known secondary structure. 
2.7 Fibrillisation of recombinant C1  
Fibrillisation followed a method previously published [36, 37]. In summary, lyophilised full 
length and C1 rPrP were reconstituted in 6 M guanidine-HCl (pH 6.0) to a concentration of 3 
mg/ml. Reaction mixtures contained 2 M guanidine-HCL, 50 mM MES, 10 mM thiourea and 
100 µg/ml PrP/C1. For assays with two proteins, each was added to a final concentration of 
50 µg/ml. To monitor fibrillisation kinetics, Thioflavin (ThT) was added (10 µM). 167 µL of 
reaction mix was dispensed into each well of a 96 well plate along with 3 Teflon balls (2.381 
mm diameter, The Precision Plastic Ball Company). The plate was incubated with shaking, 
900rpm at 37 °C in a fluorescent plate reader (Fluoroskan Ascent, Thermo Scientific). ThT 
fluorescence was measured every 5 minutes for 24 hours (excitation at 444 nm, emission at 
485 nm). Data were analysed and lag times calculated as described in Graham et al 2010 [37]. 
To account for background fluorescence, fibrillisation reactions were set up in the absence of 
PrP protein. The number of repeat fibrillisation assays (n) varied for each protein variant. For 
analysis of fibrils by other methods, separate reactions were set-up without ThT. Post-
fibrillisation, these reactions were dialysed into 10 mM sodium acetate and stored at 4 °C 
2.9 Maturation and PK digestion of fibrils  
This protocol was followed directly from Breydo et al [36]. Proteins were visualised by gel 
electrophoresis (12 % NuPAGE Bis-Tris gel, Invitrogen) and silver staining. 
2.8 Electron Microscopy  
Formvar coated copper grids were placed onto a 50 μl drop of fibril preparation (60 µg/mL in 
10 mM sodium acetate, pH 5). After 45 seconds, the grid was removed, touched to a filter 
paper to remove excess fluid, and then placed onto a drop of filtered 2% aqueous 
phosphotungstic acid for 2 minutes. Grids were then air dried before storage and examined 
using a Jeol 1200EX transmission electron microscope 
2.9 Statistical analysis  
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For analysis of all brain derived PrPC, the non-parametric Mann-Whitney U test was applied. 
For in-vitro assays, the one-tailed student T-test was applied. 
3. Results 
3.1 The quantity of PrPC C1-fragment relative to total PrPC is consistent in different areas of 
ovine brain.  
To assess quantities of the C1 fragment in specific brain areas, we measured levels of the 
PrPC C1 fragment relative to full length PrPC by semi-quantitative analysis of Western blots 
using anti-PrP antibodies BC6 (Figure 1) or Bar224. Cortex, cerebellum, midbrain, thalamus, 
hypothalamus, medulla,  pons  were compared for five Roslin sheep two of ARR/ARR and 
three of ARQ/ARQ genotypes. A representative Western blot showing relative C1 levels in 
different brain regions of an ARQ homozygous sheep is shown in Figure 1A. Relative C1 
levels varied considerably between animals (e.g. levels of C1 in the cortex ranged from 12-48 
%), however, the ranking of percentage C1 levels between areas within a single animal 
appeared consistent; therefore we normalised C1 levels for all brain areas against the cortex 
(cortex = 1) for each animal. Applying the non-parametric Mann-Whitney U-test, no 
significant differences in relative C1 levels were found between cortex and cerebellum (0.98 
± 036), thalamus (1.36 ± 0.74), hypothalamus (1.33 ± 0.84), mid brain (1.64 ± 1.36) medulla 
(1.09 ± 0.73) and pons (1.17 ± 0.94). These data are summarised in Figure 1B.  
To confirm that C1 levels are consistent across all brains areas in animals out-with our flock, 
we tested cortex, cerebellum and brainstem in a further four unrelated homozygous 
Norwegian sheep. C1 levels in cerebellum (0.78 ± 0.23) and brainstem (0.9 ± 0.54), relative 
to cortex, did not differ significantly from the Roslin sheep (data not shown). Overall, we 
found that relative C1 levels were similar across different brain regions for individual animals 
but our data suggested that relative C1 levels may vary depending on PRNP genotype. We 
therefore measured relative C1 levels as a function of PRNP genotype. 
  
3.2 The relative abundance of the PrPc C1 fragment in ovine cortex varies with the PRNP 
genotype.  
We increased the number of Roslin sheep samples per genotype to a total of 11 ARR/ARR, 
13 ARQ/ARQ and 5 VRQ/VRQ. These genotypes of sheep were selected because they are 
associated with varying susceptibility to classical scrapie. We focused on relative C1 levels in 
the cortex only, since we have shown that this area is representative for most of the brain. In 
individual animals, relative levels of the C1 fragment ranged from 14% to 77% of total PrPC. 
A representative Western blot of PrPC in the cortex of VRQ, ARQ and ARR homozygous 
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sheep is shown in Figure 2(A) and illustrates the differences in C1 levels between sheep of 
different PRNP genotype. Similar analyses were repeated for each animal and we calculated 
average C1 levels within genotype groups. Animals of the ARR/ARR genotype – associated 
with resistance to classical scrapie – had a mean relative C1 level of 52.6% (SD ± 11.9) 
which was significantly higher than the mean C1 level of 27.7% (SD ± 14.5) for ARQ/ARQ 
(p < 0.0001) and the mean C1 level of 32.6% (SD ± 8.8) for VRQ/VRQ sheep (p ≤ 0.002). 
These data are shown graphically in Figure 2B. Since there was no significant difference 
between ARQ/ARQ and VRQ/VRQ animals (from here on designated QQ171, whilst ARR 
homozygous sheep are designated RR171), which are both associated with susceptibility to 
classical scrapie, we combined data from these genotype groups. 
It has previously been reported in several species that relative C1 levels in the brain were 
around 50% of total PrPC [20-22, 25], in accordance with our ARR/ARR sheep. To confirm 
that the unexpectedly low mean C1 level in our 18 QQ171 sheep (29.1% SD ± 13) was not 
specific to these animals, we compared them to five Norwegian QQ171 sheep, which showed a 
mean relative C1 level of 27.8% (SD ± 7.5). Analysis with two additional antibodies FH10 
and JB10  replicated the pattern seen with BC6 and Bar224 making it highly unlikely that any 
of these results were significantly influenced by the choice of antibody. We conclude that 
steady state levels of the C1 fragment relative to total PrPC were 1.8 times (1.4 - 2.1, 95% 
confidence interval) higher in the cortex of RR171 homozygotes (n = 11) compared to QQ171 
sheep (n = 23). 
 
3.3 Sheep of the ARR/ARR genotype typically have undetectable levels of C2 fragment.  
In parallel to the C1 fragment, we measured the steady state levels of the C2 fragment also by 
immunoblotting with antibody BC6. Across sheep of all genotypes, the mean C2 level (for 
C2 ≠ 0) was 7.8 % (SD ± 4.8) of total PrPC, but only 11 out of 28 samples had detectable C2 
(defined here as ≥ 1% of total PrPC). A single RR171 sample out of 11 showed detectable C2, 
whereas in QQ171 samples the frequency was 10 out of 18. The RR171 samples were five 
times less likely to show C2 fragment than QQ171 genotypes (p ≤ 0.01), but no correlation 
was observed between relative levels of C1 and C2 (for C2 ≠ 0).  
 
3.4 Recombinant C1 can form amyloid fibrils in-vitro.  
Our data here show that all genotypes studied express some level of C1. To further 
investigate genotype specific effects associated with the folding pathways of the C1 
fragment, we explored in-vitro fibrillisation assays with recombinant proteins. Five proteins 
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were expressed, two represent full-length ovine PrP25-233 of sequence variants ARR and VRQ 
(designated rPrP
ARR
 and rPrP
VRQ
), expressed in pTrcHis B/Rosseta bacterial system. The 
three others represent truncated ovine PrP115-235 of sequence variants ARR, VRQ and ARQ, 
expressed in a PET-19b/BL21 (DE3) bacterial system, which are the equivalent of the C1 
fragments but which incorporate an N-terminal histidine tag to aid purification (designated 
rC1ARR, rC1VRQ, rC1ARQ). The regions of the protein expressed are shown schematically in 
Figure 3A.  
As expected, the recombinant C1 proteins were detected by immune-blotting with the C-
terminal antibody, BC6, but no reactivity was observed towards the N-terminal antibody P4 
(Figure 3B).The purity of protein was confirmed both by SDS-PAGE stained with Instant 
Blue (Figure 3C) and by mass spectrometry. Mass spectrometry revealed that the rC1 proteins 
had been correctly expressed, but also indicated small amounts of the protein that had been 
modified causing mass shifts of +178Da and +258Da (see supplementary Figure S1). Such 
modifications have been previously documented and are attributed to spontaneous alpha-N-6-
phospho-gluconoylation of the His Tag [38]. These modifications were slightly more 
abundant in the rC1
ARR 
variant, but since the levels of these modifications are already low 
and the modifications are within the octa-histidine tag, they are unlikely to impact on protein 
misfolding or stability. To check this we measured circular dichroism spectra (CD) for the 
three rC1 protein variants, which verified that all exhibited a primarily alpha-helical structure, 
characterized by spectra showing two minima at 222 nm and 208 nm, as shown in Figure 3D. 
Using CD analysis programs SELCON3 (CONTINLL) [39, 40] it was estimated that our rC1 
peptides consisted of secondary structures in the following proportions: rC1ARR was 28% 
(28%) α-helix, 21% (22%) β-sheet and 51% (51%) random coil; rC1VRQ was 42% (38%) α-
helix, 13% (18%) β-sheet and 46% (44%) random coil; rC1ARQ was 28% (34%)  α-helix, 16% 
(17%) β-sheet and 58% (49%) random coil.  
Using the five different PrP-derived recombinant proteins, fibrillisation assays were set up in 
the presence of thioflavin T (ThT). Fibril formation kinetics were measured over a 24-hour 
period and lag times were calculated as described in Graham et al. [37]. Fibrillisation 
experiments were repeated multiple times and typical fibrillisation curves for C1 fragments 
are shown in Figure 4, whilst typical curves for the full length proteins rPrP
VRQ
 and rPrP
ARR
 
are shown in Figure 7. Fibrillisation of rPrP
ARR 
and rPrP
VRQ 
showed an initial lag phase 
(nucleation) followed by a rapid increase in fluorescence on fibril growth (elongation) as 
reported previously for murine full length PrP [41, 42] and human full length PrP [43]. 
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rPrP
VRQ 
had an average lag time of 5.57 hours (SEM +/- 0.40, n =16) while with rPrP
ARR 
the 
lag time was longer (p  0.002), averaging 8.32 hours (SEM +/- 0.69, n =16).  
Fibrillisation of rC1
VRQ 
(n=24) and rC1
ARQ 
(n=14) produced curves that were qualitatively 
similar to those of the full-length variants, with average lag times of 3.98 (SEM+/- 0.34) and 
3.96 (SEM +/- 0.22) hours respectively (Figure 4). Once maximum fluorescence was 
reached, ThT fluorescence curves tended to fall to around 50 % of the maximum. This 
phenomenon of reducing fluorescence signal following fibril formation has previously been 
reported during the fibrillisation of human rPrP
90-231
. The reasons for it are yet to be fully 
explained, but Almstedt et al. suggested that aggregation of fibrils was the most likely cause, 
thereby reducing the outward facing regions available for ThT binding [43]. 
Compared to other rC1 proteins, rC1
ARR 
(n=24) showed a modified fibrillisation profile 
comprising a significantly longer lag time (p ≤ 2.5 x 10-6), on average 11.0 hours (SEM +/- 
1.0) (Figure 4) and a reduced elongation rate after nucleation. Indeed, complete fibrillisation 
often did not occur within the 24-hour time frame of the experiment; in these cases the lag 
times could not be calculated, since this calculation depends on maximal levels of ThT 
fluorescence being achieved. Figure 4 shows an example of two rC1
ARR 
reactions, one 
positive and one negative for complete fibrillisation. These results indicate that rC1
ARR 
has a 
decreased ability to form amyloid fibrils when compared to other two rC1 variants. 
To confirm that C1 proteins were producing fibrils rather than non-fibrillar, ThT-binding 
aggregates, we applied a fibril maturation assay originally described by Bocharova et al [44]. 
Fibrils composed of rPrP have a PK resistant core of10-12 kDa, but by heating PrP amyloid 
fibrils to 80 ˚C a structural change is initiated such that the PK-resistant core is extended to 
16 kDa. Protease-resistant PrP can be detected SDS-PAGE and silver staining and typical 
results are shown in Figure 5. For the full length rPrP samples, a well-defined 16 kDa band is 
evident after maturation along with the characteristic 12 and 10 kDa fragments, consistent 
with previously reported results [36, 44] and confirming the presence of fibrils. In rC1 
fibrillisation reactions along with the three bands described above, two additional PK-
resistant fragments appeared after maturation, one of the similar size to the intact rC1 protein 
(~16.6 kDa) and one of ~13 kDa. The presence of a 13 kDa band was also evident in 
maturation assays of human PrP90-231 [45] and may indicate formation of disordered 
aggregates with increased PK resistance. The 16.6 kDa band could represent an increase in 
core expansion or a structural change which alters available PK digestion sites. The 16 kDa 
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band was less intense in rC1 fibril preparations compared to rPrP preparations, suggesting 
that a reduced amount of fibrils may be produced in rC1 fibrillisation reactions.  
To further characterise rC1 amyloid fibrils, we analysed preparations by electron microscopy, 
as shown in Figure 6. Fibrils were observed in all preparations and there were no clear 
morphological differences between fibrils from different samples, although using this 
technique it was not possible to quantify the number of fibrils. Nevertheless, it is clear that 
rC1 proteins all form fibrils in a similar manner to rPrP, but that fibrillisation of the rC1
ARR
 
protein proceeds with an extended lag time and reduced growth rate compared to rC1
VRQ
 and 
rC1
ARQ
. 
3.5 rC1
ARR 
but not rC1
VRQ
 or rC1
ARQ
 inhibits fibrillisation of other PrP variants.  
In vivo, it is possible that the C1 fragment may interfere with misfolding of full length PrP
C
. 
Depending on their PRNP genotype, ovine cells will contain a mixture of full-length PrP
C
 
molecules and C1 fragments with identical or different protein sequences at ratios that vary 
from 4:1 to 1:1. To partially mimic this in vivo scenario, we performed mixed fibrillisation 
assays with both truncated and full length recombinant proteins at different ratios. 
Fibrillisation reactions were repeated multiple times and typical results for selected reaction 
mixtures are show in Figure 7. rPrP
VRQ
 was mixed at a 1:1 ratio with rC1
ARR
 (n=10), rC1
ARQ 
(n = 6) or rC1
VRQ 
(n = 10) and the lag time of fibrillisation was measured. There was no 
significant change in lag time with addition of rC1
ARQ
 (data not shown) or rC1
VRQ
 compared 
to rPrP
VRQ 
alone. However, rC1
ARR
 addition significantly increased the lag time of 
fibrillisation of rPrP
VRQ
 from 5.57 hours (SEM  ± 0.40) to 10.6 hours (SEM  ± 1.12) (p  = 5.2 
x 10
-5
). As observed with fibrillisation of rC1
ARR
, approximately 75% of the mixed assays 
containing rC1
ARR
 did not result in full fibrillisation within the time frame of the experiment 
and therefore lag times could not be calculated in these cases. When full fibrillisation was 
achieved, it was evident that the elongation phase of fibrillisation of rPrP
VRQ
 was extended 
and closely resembled those observed with rC1
ARR 
alone, with a slow ThT increase after 
nucleation and low maximum fluorescence.  
The presence of fibrils in these mixed assays was confirmed using the maturation assay, as 
shown in Figure 5, which showed 10 and 12 kDa bands as described for both rPrP species 
along with a prominent 16.6 kDa band associated with C1 fibrils alone after maturation. The 
16 kDa band which would confirm the presence of full length PrP fibrils is very faint when 
compared to maturation and PK digestion of full length rPrP alone, indicating that full length 
PrP has not formed amyloid fibrils but this mixed reaction favours the production of C1 
fibrils.  
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Reactions at a 4:1 rPrP
VRQ
: rC1
ARR
 ratio were also performed (n = 7), in which average lag 
time for fibrillisation of rPrP
VRQ
 was increased to 6.6 hours (SEM ± 1.36). In these reactions, 
fibrillisation of rPrP
VRQ
 was inhibited to less of an extent compared to the 1:1 reactions. The 
rate of elongation and maximum fluorescence were lower than seen with full length protein 
alone, with 3 out of 7 repeats failing to fibrillise fully within the time frame of the experiment 
(Figure 7). 
We then mixed rPrP
ARR
 with all three variants of C1 at a 1:1 ratio. Addition of rC1
ARR 
to 
rPrP
ARR 
(n=10) increased the average lag time only marginally from 8.3 (SEM ± 0.69) to 9.0 
(SEM ± 0.41), but reduced the rate of fibril elongation dramatically, as illustrated in Figure 7. 
In contrast, addition of rC1
VRQ 
or rC1
ARQ
 (data not shown) to rPrP
ARR 
shortened the lag time 
of fibrillisation. The early ThT fluorescence increase may represent C1 fibrillisation and 
mask the slightly later fibrillisation of rPrP
ARR
 or the addition of these C1 variants may 
increase the rate of nucleation and elongation of rPrP
ARR
. Further evidence to support the 
second of these hypotheses is the observation, in some mixed reactions, of two peaks of 
fluorescence, illustrated in the rPrP
VRQ 
+ rC1
VRQ 
fibrillisation curve in Figure 7. In these 
cases, curves of best fit could not be produced and lag times were not calculated.  
We propose that the two fluorescence maxima may represent separate fibrillisation 
mechanisms of the two protein variants, however, at this point we have no direct evidence of 
this. Across all our fibrillisation reactions, we calculated lag times, for those reactions that 
produced a maximum of ThT fluorescence, and averaged these. The results are shown 
graphically in Figure 8, from which it is clear that the rC1ARR inhibits fibrillisation of both 
full length rPrPARR and rPrPVRQ whilst rC1VRQ and rC1ARQ do not inhibit fibrillisation. 
 
4. Discussion 
The susceptibility of sheep to various natural prion diseases provides a valuable genetic 
model of disease resistance in which mechanisms of protein misfolding and 
neurodegeneration can be studied [16, 33, 46]. PRNP genetics are exploited worldwide in 
breeding programmes to manage the risk of scrapie outbreaks, despite a critical lack of 
understanding the underlying mechanisms that link PrPC variants to disease resistance. By 
revealing a molecular basis of resistance, more effective measures could be put in place both 
to restrict new prion strains from adapting to low risk PRNP genotypes and to maintain PrPC 
variants with protective potential.  
A number of in vitro studies into the molecular aspects of resistance of specific sheep 
genotypes to scrapie have probed the initial binding of cellular to disease-associated prion 
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protein prior to conversion [47, 48] or on the relative convertibility of prion protein variants 
[15, 34]. Others have tried to explain disease resistance by allele-specific expression profiles 
[47, 48], different protein conformations or different characteristics of fibrillisation and 
thermal stability [14]. Our results demonstrate that there are higher levels of PrPC α-cleavage 
fragments in sheep of the scrapie-resistant genotype ARR/ARR relative to sheep of more 
susceptible genotypes. The C1 fragment is produced by the action of an unknown ‘α-
secretase’ and high C1 levels in ARR/ARR sheep may result from an increased proteolytic 
processing of PrPARR compared to PrPARQ or PrPVRQ or due to differences in the half-lives of 
the allotypic C1 fragments. The former may be explained by conformational differences 
leading to increased presentation of the cleavage site for the α-secretase or by the extended 
presence of PrPARR within the Golgi apparatus increasing the chance of interacting with the 
α-secretase [49].  
Setting the reason for the differences aside, the correlation between a high C1 level and 
scrapie resistance is supported by similar evidence from cell culture assays and transgenic 
mouse models. Lewis et al [32] showed that neuronal and non-neuronal cell lines with higher 
levels of α-cleavage show more resistance to prion infection and concluded that this cleavage 
is the most important factor in the selective vulnerability to prions [32]. Scrapie challenges in 
transgenic mice expressing only C1 protein [31] showed  that C1 alone does not act as a 
substrate for conversion to PrPSc. Over-expression of C1 in the presence of full length PrPC 
slowed accumulation of PrPSc and extended the incubation period of disease in these 
transgenic mice, supporting the view that C1 may inhibit some unknown pathway in the 
conversion of PrPC to PrPSc.  
Along with the possible effects of C1, the corresponding product of α-cleavage, N1 has been 
shown to possess neuroprotective functions. For example, N1 can inhibit staurosporine 
induced caspase-3 activation through the p53 pathway [50] and addition of a recombinant N1 
isoform in cultured cells also shows dose dependent neuroprotective effects [51]. Although 
we have not measured levels of N1 in our sheep brain samples, we can infer its presence from 
the levels of the corresponding C1 fragment and it is likely, therefore, that the increased 
levels of this fragment in disease-resistant animals will represent an additional benefit in 
protection against the neurodegeneration associated with prion disease.  
Our observation that relative C2 levels in ARR/ARR sheep were significantly reduced when 
compared to the other genotypes is surprising, since there is little supporting evidence of an 
inverse correlation between α – and β–cleavage in healthy individuals. The small C2 
percentage in sheep with QQ171 genotypes may represent an additional susceptibility-
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enhancing factor which remains to be investigated in more detail. Truncated recombinant PrP 
(90-231), representing the C2 isoform, has a similar ability to aggregate and fibrillise as full 
length recombinant PrP [52]. 
Since PrPARR associated with prion resistance produces increased C1 levels in vivo and the 
presence of C1 protein reduces PrP conversion levels in cell culture [32] and transgenic mice 
[31] we investigated whether the C1 fragment could interfere with misfolding of PrP . We 
produced various allotypes of recombinant C1 and full length PrP and assessed their ability to 
form amyloid fibrils in vitro. All variants had the ability to form amyloid fibrils as confirmed 
by increases in ThT fluorescence during fibrillisation, the presence of a 16 kDa protease-
resistant core after maturation [44] and the presence of fibrillar aggregates visualised by 
electron microscopy.  
rC1ARR had a significantly longer lag time of fibrillisation and an altered fibril growth phase 
when compared to both other allotypic forms of rC1 and rPrPC. Often reactions with rC1ARR 
would fail to fibrillise fully within the time frame of the experiment indicating that this 
protein has a reduced potential to form fibrils. Similar polymorphism dependent differences 
have been reported with in vitro conversion of human rPrP90-231 [53-55]. 
When mixed with other protein variants at a ratio of 1:1, to represent a situation similar to 
heterozygous brain tissue, rC1ARR inhibited fibril formation whilst rC1ARQ and rC1VRQ did 
not. In fibrillisation reactions with a rPrPC: rC1 ratio of 4:1, inhibition was observed but the 
increase in lag time was less dramatic suggesting that the rPrP: rC1 ratio could be an 
important factor if similar inhibitory mechanisms apply in vivo.  
Our findings show that rC1ARR can inhibit the initial nucleation of amyloid fibrils and slow 
the elongation phase of fibrillisation, but it is unclear if C1 also prevents conversion of PrPC 
to PrPSc. Westergard et al hypothesised that C1 acts as competitor for the binding of PrPC to 
PrPSc, thereby delaying the onset of disease [31]. We expand on these results by showing that 
rC1 can directly inhibit the formation of rPrP amyloid fibrils in the absence of PrPSc and we 
believe that there may be two mechanisms explaining this inhibition. The rC1 protein may 
bind to rPrP and prevent further interaction with other rPrP proteins thereby inhibiting the 
formation of an initiating nucleus. Alternatively, the rC1 protein may become incorporated 
into amyloid fibrils of rPrP, which would interfere with subsequent elongation of the fibrils, 
perhaps by inducing the formation of disordered aggregates. Since the addition of rC1ARR 
both increases the lag time and alters the elongation phase, both putative mechanisms may 
occur simultaneously.  
In contrast to the findings by Westergard et al in our in vitro assays only one out of three 
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ovine C1 sequences had an inhibiting effect on fibril formation, indicating it is the arginine at 
position 171 specifically which is responsible for the effects seen. Wild type, ovine C1ARQ 
appeared not to affect fibril formation in vitro, whereas mouse wild type C1, which is 
different from sheep C1ARQ by only nine amino acid changes - has a delaying effect on 
development of TSE disease in vivo [31]. It remains to be established whether this indicates 
that the inhibition mechanism for the seeded and un-seeded nucleation or elongation is 
different or that the effects of C1 on prion replication are amplified in an in-vivo situation. 
The dominant negative inhibitory effect of C1 may be a crucial component in defining 
susceptibility and incubation periods in sheep of heterozygous PRNP genotypes. 
Experimental scrapie in VRQ/ARR sheep can lead to incubation periods twice as long as for 
VRQ/VRQ sheep and longer than VRQ/ARQ [9, 56, 57]. Furthermore, in experimental BSE, 
incubation periods in sheep of the ARQ/ARR genotype can be four times as long as for 
ARQ/ARQ sheep [58] (Goldman et al unpublished). Our data indicate that the ratio of full-
length rPrPC and rC1 fragment influences the strength of inhibition. Based on our results the 
ratio between rC1ARR and rPrPVRQ should be close to equal in VRQ/ARR sheep, whilst in 
ARQ/ARR sheep there should be approximately twice as much rC1ARR than rPrPARQ, 
supporting the idea that C1 fragments indeed play a part in scrapie pathogenesis. 
The ability of rC1ARR to inhibit conversion of rPrP makes it a possible therapeutic target in 
the treatment of prion disease. The possible effects of C1 protein if applied exogenously or 
increasing the levels of α-cleavage through manipulation of α-secretase in the in the early 
stages of TSE infection may slow disease progression, and warrants further investigation.  
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Figure 1 – Measurement of C1 fragment in different brain areas of the same animal by 
western blot.  
A: Representative Western blot of seven brain areas from an ARQ/ARQ sheep. 10% brain 
homogenate was treated with PNGase F and the membrane was probed with BC6 antibody. * 
Full length PrPC, **C2, ***C1.  These bands were measured by densitometry and C1 levels 
were calculated as a percentage of total PrPC for each brain area. B: Graph comparing 
average levels of C1 in the cortex with six brain areas. C1 data from the six other brain areas 
was normalized against cortex (cortex = 1) for each animal.  
 
Figure 2 – Comparison of relative C1 levels in the ovine cortex of sheep with varied 
susceptibility to scrapie.  
A: Representative Western blots from each genotype tested (ARR/ARR, ARQ/ARQ and 
VRQ/VRQ). 10% brain homogenate was treated with PNGase F and the membrane was 
probed with BC6 antibody. * Full length PrPC, **C2, ***C1. B: Graph showing the average 
C1 values as a percentage of total PrP as measured by densitometry.  Each sample was blotted 
and measured a minimum of twice and the average for each animal was plotted, ARR/ARR 
(n= 11), ARQ/ARQ (n=13), VRQ/VRQ (n=5). An overall average for each genotype was 
calculated and compared statistically using the Mann-Whitney U test. 
Figure 3 – Characterisation of rC1 proteins.  
A: Diagrammatic representation of recombinant full length and truncated C1 protein. C1 was 
expressed with His-Tag to aid purification in the absence of the N-terminal region. B: 
Western blots of rC1 proteins, probed with monoclonal antibodies P4 (epitope 89-104) and 
BC6 (epitope 146-154). Lane 1: rC1ARR; Lane 2: rC1ARQ, Lane 3: rC1VRQ. rC1 was not 
recognized by P4 but showed binding to BC6. C: All variants of recombinant protein 
expressed were separated by SDS-page and stained with Instant Blue to confirm purity. Lane 
1: rPrPARR, Lane 2: rPrPVRQ , Lane 3: rC1ARR, Lane 4: rC1ARQ, Lane 5: rC1VRQ .  D: Circular 
Dichroism analysis of three C1 variants to assess secondary structure. 
 
Figure 4 –Kinetics of rC1 fibrilisation measured by ThT fluorescence.  
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Typical fibrillisation curves for each rC1 variant. rC1ARQ and rC1VRQ have short lag times 
followed by a rapid elongation phase. rC1ARR often did not reach fibrillisation within the time 
frame of the experiment, described as negative for fibrillisation ( rC1ARR-ve).  
Figure 5 – Maturation and PK digestion of PrP and C1 fibrils.  
0.5 µg of recombinant protein was untreated (Lane 1), PK treated at a ratio of PrP:PK (Lane 
2), or matured by heating to 80°C followed by PK treatment (Lane 3). Matured fibrils (Lane 
3) show increased PK resistance relative to non-matured fibrils. rPrP reactions show a 16 kDa 
band after maturation which confirms the presence of fibrils, highlighted by the black box. In 
rC1 preparations, bands with increased PK resistance of 16.6 kDa, 16 kDa and 13 kDa are 
present, highlighted by the dotted box. Mixed reactions of rPrPVRQ and rC1 have a prominent 
band of 16.6 kDa with a faint 16kDa band, highlighted by the dashed box. 
Figure 6 – Electron Microscopy of rC1 and rPrP fibrils.  
Fibrils were produced in the absence of ThT and dialysed into sodium acetate. Fibrils were 
viewed on a transmission electron microscope. Images were taken at x 5000 and x 20000. A: 
rC1ARR, B: rC1ARQ, C: rC1VRQ, D: rPrPARR, E: rPrPVRQ. 
Figure 7 – Fibrillisation of rPrP in the presence of rC1.  
Typical fibrillisation curves for mixed reactions. Addition of C1ARR to full length PrPARR and 
PrPVRQ at both a 1:1 and a 4:1 ratio extends the lag time of fibrillisation, slows the rate of ThT 
fluorescence increase and lowers maximum fluorescence. These effects are reduced in 
experiments at 4: 1 ratio. During mixed reactions, two peaks of fluorescence were evident in 
some wells, illustrated in rPrPVRQ + rC1VRQ 1:1. 
 
Figure 8 – Addition of rC1ARR increases lag time of fibrillisation of other rPrP variants.  
A) Graph showing average lag time for rPrPVRQ : rC1ARR, rC1ARQ, rC1VRQ mixed fibrillisation 
reactions along with the frequency of reactions failing to fibrillise within the 24 hour time 
frame of the experiment, calculated as a percentage of total reactions. B) As described for 
graph A) for rPrPARR : rC1ARR, rC1ARQ, rC1VRQ mixed fibrillisation reactions. 
 
Supplementary Figure S1    Mass spectrum of rC1ARR and rC1VRQ  
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Supplementary Figure S1 
(A) Mass spectrum and (inset) deconvoluted mass spectrum of the expressed rC1ARR 
fragment.  
The spectrum consists of a single major charge envelope, labelled with ‘A’ along with the 
charge state of each of the species (20+, 19+ etc) and the mass/charge ratio at which each 
peak occurs. Deconvolution of the spectrum shows the presence of a single major species 
(labelled Mr(A) 16505.9) which represents the unmodified protein. The measured 
molecular weight of the unmodified protein (16505.9 Da) is in excellent agreement with 
the theoretical molecular weight calculated from the sequence of 16506.1 Da. A second 
species (labelled Mr(B) 16764.1) occurs at a molecular weight of 258 Da higher than the 
unmodified protein whilst a third (labelled Mr (C) 16684.7) is 178 Da higher in mass than 
the unmodified protein. These species are consistent with previously reported 
modifications within the His Tag region of the protein, specifically attributed to 
spontaneous alpha-N-6-phospho-gluconoylation.  
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(A) Mass spectrum and (inset) deconvoluted mass spectrum of the expressed rC1VRQ 
fragment.  
The spectrum consists of a single major charge envelope, labelled with ‘A’ along with the 
charge state of each of the species (20+, 19+ etc) and the mass/charge ratio at which each 
peak occurs. Deconvolution of the spectrum shows the presence of a single major species 
(labelled Mr(A) 16505.9) which represents the unmodified protein. The measured molecular 
weight of the unmodified protein (16505.9 Da) is in excellent agreement with the theoretical 
molecular weight calculated from the sequence of 16506.1 Da. A second species (labelled 
Mr(B) 16763.5) occurs at a molecular weight of 258 Da higher than the unmodified protein 
whilst a third (labelled Mr (E) 16684.1) is 178 Da higher in mass than the unmodified 
protein. These species are consistent with previously reported modifications within the His 
Tag region of the protein, specifically attributed to spontaneous alpha-N-6-phospho-
gluconoylation. The levels of modifications are lower for the VRQ variant than for the ARR 
variant, but in both cases appear to be present in less than 15% of the protein. 
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